Drug
Osavampator
Osavampator: highest development phase Phase 3, developed by Neurocrine Biosciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Osavampator NCT07196501 | Phase 3 | Major Depressive Disorder |
Latest
No recent events.
Follow Osavampator on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.